Cite
Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers.
MLA
Smith, Neil, et al. “Phase I Clinical Evaluation of CNSA-001 (Sepiapterin), a Novel Pharmacological Treatment for Phenylketonuria and Tetrahydrobiopterin Deficiencies, in Healthy Volunteers.” Molecular Genetics & Metabolism, vol. 126, no. 4, Apr. 2019, pp. 406–12. EBSCOhost, https://doi.org/10.1016/j.ymgme.2019.02.001.
APA
Smith, N., Longo, N., Levert, K., Hyland, K., & Blau, N. (2019). Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers. Molecular Genetics & Metabolism, 126(4), 406–412. https://doi.org/10.1016/j.ymgme.2019.02.001
Chicago
Smith, Neil, Nicola Longo, Keith Levert, Keith Hyland, and Nenad Blau. 2019. “Phase I Clinical Evaluation of CNSA-001 (Sepiapterin), a Novel Pharmacological Treatment for Phenylketonuria and Tetrahydrobiopterin Deficiencies, in Healthy Volunteers.” Molecular Genetics & Metabolism 126 (4): 406–12. doi:10.1016/j.ymgme.2019.02.001.